Abstract
Biological therapy is successfully used in the treatment of autoimmune diseases, which are resistant/failed to conventional therapy. There are currently available many biologies with different mechanism of action and indication in rheumatology, dermatology and gastroenterology.
Adalimumab belongs to the group of inhibitors of tumor necrosis factor a, and is used in the therapy of rheumatoid arthritis, ankylosing spon-dylitis, juvenile idiopathic arthritis and in gastroenterological indication for ulcerative colitis and Crohn's disease. Adalimumab is a fully human monoclonal antibody, which is administered in biweekly dosing re-gimen.
This paper will summarize the basic pharmacokinetic and pharmacodynamic properties and in-dications of adalimumab and its effectiveness will be demonstrated on the case reports of two patients.